20:48:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaSmall Cap Helsinki
Optomed är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling av specialiserade ögonkameror. Utveckling sker av både hård- och mjukvara som vidaresäljs under olika varumärken. Verksamhet innehas på global nivå, med störst närvaro inom den nordiska marknaden. Kunderna består av forskningsinstitut samt sjukhus. Huvudkontoret ligger i Oulu.


2023-11-03 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-05-10 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-09-06 Extra Bolagsstämma 2022
2022-08-04 Kvartalsrapport 2022-Q2
2022-05-11 Ordinarie utdelning OPTOMED 0.00 EUR
2022-05-10 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning OPTOMED 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning OPTOMED 0.00 EUR
2020-06-11 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2022-02-07 14:02:00

Optomed Plc         Inside Information              7 February 2022 at 15.02, Helsinki

Optomed Announces Clinical Trial Results

Optomed announces the results from the prospective, multi-center clinical trial intended to assess its handheld fundus camera Aurora together with AEYE Health's AI for autonomous detection of more than mild diabetic retinopathy, a blinding eye disease estimated to affect over 190 million people globally by the year 2030. Optomed and AEYE Health previously announced their cooperation to introduce an AI-assisted fundus camera Aurora AEYE and conduct a clinical trial with the aim to receive U.S. FDA clearance for autonomous AI for retinal screening for more than mild diabetic retinopathy on 18th September 2020.

Among patients positive for more-than-mild diabetic retinpathy, the combined product, Aurora AEYE detected 91,9 percent (sensitivity), while patients without the eye disease were correctly identified 93,0 percent of the time (specificity). The observed imageability was over 99 percent.

Optomed CEO, Seppo Kopsala, commented: "Completing the clinical trial with such promising results is the first step of our plan to receive the U.S. FDA clearance for the AI-assisted fundus camera Aurora AEYE. The observed sensitivity and specificity and especially the high imageability achieved hold the promise of moving forward together with AEYE Health to introduce the first handheld AI fundus camera in the U.S. market"

AEYE Health CEO, Zack Dvey-Aharon, Ph.D., comments: "We are thrilled that our AI exhibited such high efficacy on a portable camera and especially given the use of only a single image obtained per eye. We believe this achievement will truly revolutionize and democratize retinal screening. Optomed is a fantastic partner and we look forward to delivering on this promise. "

Optomed Plc

Further enquiries

Seppo Kopsala, CEO, seppo.kopsala@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company's products are sold via various sales channels in over 60 countries globally


CAUTION - Investigational device.  Limited by United States law to investigational use.